Alexander Kohlmann

Oncology R&D, AstraZeneca
Melbourn, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.

Journal: PloS one

Published: July 14, 2023

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.

Journal: The Journal of molecular diagnostics : JMD

Published: December 21, 2022

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 04, 2021

A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.

A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.

Journal: Scientific reports

Published: March 05, 2021

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

Journal: The New England journal of medicine

Published: April 29, 2020

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.

Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 02, 2019

Current status and trends in the diagnostics of AML and MDS.

Current status and trends in the diagnostics of AML and MDS.

Journal: Blood reviews

Published: March 20, 2018

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

Journal: Critical reviews in oncology/hematology

Published: December 01, 2017

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 19, 2017

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice.

Journal: ESMO open

Published: June 23, 2017

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Journal: JAMA

Published: May 12, 2017

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Journal: British journal of cancer

Published: March 05, 2017

Showing 1-12 of 79

Last Updated: 09/26/2026